• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Scienture Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    3/13/25 4:27:27 PM ET
    $SCNX
    Other Pharmaceuticals
    Health Care
    Get the next $SCNX alert in real time by email
    false 0001382574 0001382574 2025-03-10 2025-03-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): March 10, 2025

     

    SCIENTURE HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   001-39199   46-3673928

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File No.)

     

    (I.R.S. Employer

    Identification No.)

     

    6308 Benjamin Rd, Suite 708

    Tampa, Florida 33634

    (Address of Principal Executive Offices)

     

    (866) 468-6535

    (Registrant’s Telephone Number)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.00001 per share   SCNX  

    The Nasdaq Stock Market LLC

    (The Nasdaq Capital Market)

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    The information set forth in Item 5.02 below is incorporated herein by reference into this Item 1.01.

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On March 13, 2025, the Board of Directors of Scienture Holdings, Inc. (the “Company”) appointed Eric Sherb to serve as the Company’s Chief Financial Officer effective as of March 13, 2025 (the “Effective Date”). Mr. Sherb (age 38), has served as an accounting consultant for the Company since 2023. The Company’s addition of Mr. Sherb as its full-time Chief Financial Officer brings 16 years of experience in accounting advisory, auditing, and mergers and acquisitions, with substantial experience in financial reporting for public entities.

     

    Mr. Sherb will succeed Prashant Patel, who previously served as the Company’s Interim Principal Financial/Accounting Officer. Mr. Patel notified the Company’s Board of Directors of his intention to resign his position as Interim Principal Financial/Accounting Officer effective as of the Effective Date. Mr. Patel will continue to serve as the Company’s President and Chief Operating Officer. Mr. Patel’s decision to resign as the Company’s Interim Principal Financial/Accounting Officer is not the result of any dispute or disagreement with the Company, the Company’s management or the Company’s Board of Directors on any matter relating to the Company’s operations, policies or practices.

     

    In connection with Mr. Sherb’s appointment as Chief Financial Officer, the Company and EMS Consulting Services, Inc., an entity controlled by Mr. Sherb, entered into an independent contractor agreement (the “Agreement”) whereby Mr. Sherb has agreed to perform, on a full-time basis, all services (a) assigned by the Company’s Chief Executive Officer and (b) otherwise necessary or convenient in fulfilling the obligations associated with serving as the Chief Financial Officer of a publicly-traded company with common stock listed on The Nasdaq Marketplace LLC. In exchange, the Company has agreed to pay Mr. Sherb (i) an annual cash fee of $100,000; (ii) an annual grant of shares of the Company’s common stock equal to an aggregate amount of $50,000, to be issued as soon as reasonably practicable upon signing of this Agreement and every year thereafter during the term of the Agreement; and (c) an annual discretionary bonus in an amount, if any, determined in the sole discretion of the Company’s Board of Directors. The Agreement became effective on the Effective Date and will continue until terminated by the Company or Mr. Sherb on no less than 14 days’ prior notice. The Agreement is filed as Exhibit 5.1 hereto and is incorporated herein by reference.

     

    The Company has not been party to any transactions with Mr. Sherb since the beginning of the Company’s last fiscal year where the amount involved exceeds the lesser of $120,000 or on percent of the average of the Company’s total assets at year-end for the last two completed fiscal years.

     

     

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    Scienture Holdings, Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders both (the “Annual Meeting”) virtually via a live webcast on March 10, 2025. The Company’s stockholders voted on five proposals at the Annual Meeting, each of which is listed below and described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on January 27, 2025, as modified on February 18, 2025. With respect to each proposal, holders of the Company’s common stock, par value $0.00001 (“Common Stock”) were entitled to cast one vote per share of Common Stock held as of the close of business on the record date of January 9, 2025. At the beginning of the Annual Meeting, holders of Common Stock representing 6,289,061 votes were represented in person or by proxy at the Annual Meeting, which represented 71.87% of the voting power of the 8,750,582 shares of Common Stock entitled to vote at the Annual Meeting and constituted a quorum for the transaction of business.

     

    At the Annual Meeting, the Company’s stockholders voted on the following proposals:

     

      1. To elect five directors to serve on the Board until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier resignation or removal;

     

      2. To ratify the appointment of CM3 Advisory as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;

     

      3. To consider and approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers; and

     

      4. To consider and select the preferred frequency for conducting future stockholder advisory votes on named executive officer compensation on a non-binding, advisory basis.

     

    The final results of voting on each of the proposals presented at the Annual Meeting, as certified by the Company’s independent inspector of election, are set forth below.

     

    Proposal No. 1: Election of Directors.

     

    The stockholders elected each of the five director nominees to serve on the Company’s Board of Directors until the next Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier resignation or removal. The results of the vote taken were as follows:

     

    Nominee  Votes For  Votes Against  Abstentions  Broker Non-Votes
    Surendra Ajjarapu  6,225,992  1,226  12,582  49,261
    Donald G. Fell  6,199,653  1,243  38,904  49,261
    Mayur Doshi  6,220,506  1,242  18,052  49,261
    Subbarao Jayanthi  6,220,506  1,238  18,056  49,261
    Shankar Hariharan  5,157,373  1,064,371  18,056  49,261

     

    Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm

     

    The stockholders ratified the appointment by the Board’s Audit Committee of CM3 Advisory as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the vote taken were as follows:

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    6,275,649  823  12,589  —

     

    Proposal No. 3: Approval, on a Non-Binding, Advisory Basis, of the Compensation of the Company’s Named Executive Officers

     

    The stockholders approved the non-binding advisory resolution approving the compensation of the Company’s named executive officers. The results of the vote taken were as follows:

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    6,270,914  5,494  12,653  —

     

     

     

     

    Proposal No. 4: Approval, on a Non-Binding, Advisory Basis of the Frequency of Conducting Future Stockholder Advisory Votes on Named Executive Officer Compensation

     

    The stockholders voted in favor of “1 Year” as the preferred frequency for holding future advisory votes to approve the compensation of the Company’s named executive officers. The results of the vote taken were as follows:

     

    Shares Voted

    For 1 Year

     

    Shares Voted

    For 2 Years

     

    Shares Voted

    For 3 Years

      Abstentions  Broker Non-Votes
    3,829,343  503  2,393,125  16,829  49,261

     

    Proposal No. 5: Approval of Adjournment of the Annual Meeting, if Necessary or Appropriate

     

    The stockholders of the Company approved a proposal to adjourn the Annual Meeting to a later date or dates, if necessary or appropriate, including to solicit additional proxies if there were insufficient votes to approve the presented proposals or to constitute a quorum. Although this proposal was approved by the Company’s stockholders, because there was a quorum present and there were sufficient votes represented at the time of the Annual Meeting to approve the proposals, adjournment of the Special Meeting was deemed unnecessary. The results of the vote taken were as follows:

     

    Votes For  Votes Against  Abstentions  Broker Non-Votes
    6,263,377  12,498  13,186  —

     

    Item 9.01. Financial Statements and Exhibits.

     

    Exhibit No.   Description
    5.1   Independent Contractor Agreement by and between Scienture Holdings, Inc. and EMS Consulting Services, LLC.
    104   Cover Page Interactive Data File (embedded with the Inline XBRL document).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      SCIENTURE HOLDINGS, INC.
         
      By: /s/ Surendra Ajjarapu
        Surendra Ajjarapu
        Chief Executive Officer
    Date: March 13, 2025    

     

     

     

    Get the next $SCNX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCNX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCNX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Scienture Holdings Inc.

      10-Q - Scienture Holdings, Inc. (0001382574) (Filer)

      5/12/25 5:30:35 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form 424B3 filed by Scienture Holdings Inc.

      424B3 - Scienture Holdings, Inc. (0001382574) (Filer)

      4/24/25 4:05:28 PM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Scienture Holdings Inc.

      EFFECT - Scienture Holdings, Inc. (0001382574) (Filer)

      4/14/25 12:15:17 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care

    $SCNX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

      TAMPA, FL, April 22, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to announce the initiation of supply chain activities by its wholly owned subsidiary Scienture, LLC to manufacture launch quantities of ArbliTM (losartan potassium) Oral Suspension, 10 mg/mL for the intended commercial launch of the product in July 2025. Scirenture, LLC's contract manufacturing partner, Saptalis Pharmaceuticals, LLC

      4/22/25 8:04:59 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

      TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) (the "Company"), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, announced the divestiture of its legacy Healthcare IT and Wholesale Operations subsidiaries Integra Pharma Solutions (IPS), Bonum Health, Inc., and Softell, Inc. to Tollo Health, Inc. for a total consideration of $5 million. The divestitures are part of a broader strategic realignment at the Company designed to sharpen operatio

      4/8/25 8:05:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care
    • Scienture Holdings, Inc. Issues Annual Letter to Shareholders

      TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ:SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, bringing to market, and distributing novel specialty products to satisfy unmet market needs, is pleased to provide this annual update from its Chief Executive Officer, Surendra Ajjarapu, to its stockholders. This time last year, Scienture Holdings, Inc. (f.k.a. TRxADE Health, Inc.). was focused on health services IT assets and operations aimed at digitalizing the retail pharmacy experience. The primary operations were conducted through

      4/3/25 8:26:00 AM ET
      $SCNX
      Other Pharmaceuticals
      Health Care